News Image

Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress

Provided By GlobeNewswire

Last update: Feb 25, 2025

 Achieved Q4 2024 and full year 2024 OJEMDAâ„¢ (tovorafenib) net product revenues of $29.0 million and $57.2 million, respectively

Ended 2024 with $531.7 million in cash, cash equivalents and short-term investments

Read more at globenewswire.com

DAY ONE BIOPHARMACEUTICALS I

NASDAQ:DAWN (7/21/2025, 8:00:01 PM)

Premarket: 6.4 0 (0%)

6.4

0 (0%)



Find more stocks in the Stock Screener

Follow ChartMill for more